The pharmaceutical sector veteran announced its latest major asset buy. It has agreed to purchase one of its peers.

Receiving steady dividend payouts is always a great feeling, as paydays are always the best. Of course, most dividends are paid quarterly.

Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.

Other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of AbbVie's buyout of ImmunoGen.

ImmunoGen (IMGN) shares skyrocketed over 80% in early trading Thursday after AbbVie (ABBV) agreed to buy the rival biotech firm for $10.1 billion to expand its cancer drug portfolio.

AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 a share.

AbbVie has consistently been one of the best-performing Dividend Kings over the past 10 years. With its flagship drug in decline, however, the company's shares have faltered in 2023.

AbbVie said on Thursday it will buy drugmaker ImmunoGen for $10.1 billion, boosting its presence in the market for cancer treatments.

AbbVie Inc. ABBV, +0.30% announced Thursday an agreement to buy cancer treatment developer ImmunoGen Inc. IMGN, +0.50% in a cash deal valued at $10.1 billion. Under terms of the agreement, AbbVie w...

A proven track record of putting shareholders first is part of the litmus test that I use before buying stocks. AbbVie's recent 4.7% dividend hike builds on an impressive dividend growth streak tha...

Blue chip stocks are generally a strong investment for any stage of the economic cycle and tend to take advantage of overarching trends. That remains as true today as it was yesterday and will be t...

As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).

Value stocks have underperformed since 2006. However, I expect a shift in market dynamics, particularly for healthcare stocks. AbbVie is a compelling value play with a 4.5% yield, strong performanc...

With 2023 drawing to a close, it's time to start looking at 2024 and what it may bring to investors. The number one item on the list is uncertainty.

The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.